UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 13, 2021

Century Therapeutics, Inc.
(Exact name of registrant as specified in its charter)

Delaware	**001-40498**	**84-2040295**
(State or other jurisdiction of incorporation or organization)	(Primary Standard Industrial Classification Code Number)	(I.R.S. Employer Identification No.)

3675 Market Street **Philadelphia, Pennsylvania** (Address of principal executive offices)	**19104** (Zip Code)

Registrant's telephone number, including area code: **(267) 817-5790**

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	**Trading Symbol**	**Name of Exchange on Which Registered**
Common Stock, par value $0.0001 per share	**IPSC**	**Nasdaq Global Select Market**

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 **Other Events**

On October 13, 2021, the Company updated information reflected in a slide presentation, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Representatives of the Company will use the updated presentation in various meetings from time to time.

Item 9.01 **Financial Statements and Exhibits**

(d) Exhibits

Exhibit No.	Document
99.1	Presentation of Century Therapeutics, Inc., dated October 13, 2021
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CENTURY THERAPEUTICS, INC.

By: /s/ Osvaldo Flores, Ph.D.
Name: Osvaldo Flores, Ph.D.
Title: President and Chief Executive Officer

Date: October 13, 2021


CENTURY
THERAPEUTICS
CORPORATE OVERVIEW
October 2021

FORWARD-LOOKING STATEMENTS

This presentation contains forward-looking statements within the meaning of, and made pursuant to the safe harbour provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this document, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding possible or assumed future results of operations, business strategies, research and development plans, regulatory activities, market opportunity, competitive position and potential growth opportunities are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause the our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "might," "will," "should," "expect," "plan," "aim," "seek," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "forecast," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this presentation are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect the our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this presentation and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control, including, among others: our ability to successfully advance our current and future product candidates through development activities, preclinical studies, and clinical trials; our reliance on the maintenance on certain key collaborative relationships for the manufacturing and development of our product candidates; the timing, scope and likelihood of regulatory filings and approvals, including final regulatory approval of our product candidates; the impact of the COVID-19 pandemic on our business and operations; the performance of third parties in connection with the development of our product candidates, including third parties conducting our future clinical trials as well as third-party suppliers and manufacturers; our ability to successfully commercialize our product candidates and develop sales and marketing capabilities, if our product candidates are approved; and our ability to maintain and successfully enforce adequate intellectual property protection. These and other risks and uncertainties are described more fully in the "Risk Factors" section of our most recent filings with the Securities and Exchange Commission and available at www.sec.gov. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in the our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

CENTURY THERAPEUTICS - EMERGING LEADER IN iPSC CELL THERAPIES



WE ARE BUILDING A NEXT GENERATION CELL THERAPY PLATFORM



CENTURY THERAPEUTICS

NEXT GENERATION ALLOGENEIC iPSC-BASED PLATFORM
Hypoimmunogenic products generated with Allo-Evasion™ technology

ALLO-EVASION™ PRODUCES HYPOIMMUNOGENIC CELLS

- To potentially prevent graft rejection by patient and enhance persistence

FIT-FOR-PURPOSE PRODUCTS WITH 6+ GENE EDITS

- Cutting edge CRISPR gene editing

MULTISPECIFIC TUMOR TARGETING

- CAR engineering with VHH technology

CAR-iNK AND CAR-iT CELL PLATFORMS

- Access to both cell platforms provides optionality and potential opportunity to develop combination regimens

PROVEN LEADERSHIP TEAM

Osvaldo (Lalo) Flores, CEO

Hy Levitsky, President R&D

Adrienne Farid, COO

Greg Russotti, CTO

Luis Borges, CSO

Michael Diem, CBO

FOUNDATIONAL INVESTMENTS IN iPSC KNOW-HOW AND MANUFACTURING

Significant acceleration of platform and product development

iPSC License and collaboration agreement established in 2018

- Access to clinical grade iPSC lines
- Exclusive IP and know-how to generate immune effector cells using feeder-free methods (NK, T, Mac, DC)
- Dedicated FCDI GMP manufacturing capacity for Century's product candidates
- Leveraging two decades of research & investment at University of Wisconsin and FCDI

FUJIFILM Value from Innovation

Cellular Dynamics

In-House Manufacturing accelerates learnings and enables faster product iteration

- Century facility expected to be operational by early 2022
  - 53,000 ft^2 facility
  - Designed to produce multiple immune cell types
- Two sites provides optionality and maximizes flexibility

CENTURY THERAPEUTICS

CRYOPRESERVED DRUG PRODUCT POTENTIALLY ENABLES IMMEDIATE DOSING AT CLINICAL SITES



- Ability of NK cells to withstand cryopreservation depends not only on the freezing step itself, but on multiple factors in the entire process preceding and following freezing
- All factors are being addressed to characterize the impact of cryopreservation on the NK cell product (especially its impact on yield, activity, stability and consistency)

iPSC TECHNOLOGY CAN OVERCOME LIMITATIONS OF DONOR DERIVED PLATFORMS

Allogeneic, donor-derived



Multiple donors

Fewer doses per batch

- Complex manufacturing, heterogeneous product, limited scale
- Limited genetic engineering options

Allogeneic, iPSC-derived



Single Donor

Greater doses per batch

- Efficient manufacturing, homogeneous product, greater scale
- Likely unlimited genetic engineering options

CENTURY THERAPEUTICS

INTEGRATED CELL ENGINEERING AND MANUFACTURING

Platform allows for rapid product iteration and high-quality control standards



Precision editing

- Proprietary, high efficiency CRISPR-mediated homology directed repair reduces off-target integration
- Stepwise gene editing avoids risky multiplex modification and structural variants
- Safety switch enables elimination if necessary

Clonal master cell banking

- Master cell banks (MCB) generated from engineered single cell clone to produce uniform products
- Comprehensive characterization with multiple, complementary methods
- Evaluation performed on homogeneous bank for increased detection

High quality product

- Manufacturing starts with MCB confirmed to be free from genetic aberrations
- Genetic safety monitored at multiple points of manufacturing process through drug production

CENTURY THERAPEUTICS

Reduced Risks

Increased Detection

Quality Control

CENTURY'S CRISPR-MEDIATED iPSC GENE EDITING

Highly uniform product candidates derived from fully characterized single-cell clones

Proprietary CRISPR-MAD7 mediated homology directed repair (HDR)

- MAD7 licensed from Inscripta. Methodology developed at Century
- HDR technology enables precise gene KOs and transgene KIs
- CRISPR protein and guide RNAs delivered using RNP (non-viral)

Fully characterized, homogeneous drug products

- Sequential gene editing steps allow:
  - Introduction of multiple gene modifications
  - Limit alterations and structural variants (i.e., translocations, inversions)
- Master cell banks (MCBs) generated from single-cell clones
- MCBs fully characterized and de-risked genetically
  - Whole genome sequencing
  - Copy number variation (CNV) analysis
  - Transgene copy number by ddPCR

iPSC Precision Engineering



CRISPR-mediated HDR (MAD7)

CENTURY'S DIFFERENTIATED APPROACH TO OPTIMIZING ANTI-TUMORAL RESPONSE



CENTURY THERAPEUTICS

OVERCOMING ALLOREACTIVITY CHALLENGES

Current limitations



Graft versus Host Disease
- Donor T cells recognize patient as non-self

Alloreactive Rejection
- Patient/host recognizes allogeneic product as foreign

Century's solution



Prevention of Graft versus Host Disease
- GvHD is circumvented with Trusted TCR

Avoids Alloreactive Rejection
- Allo-evasion™ engineering enables the avoidance of host detection and destruction

CENTURY THERAPEUTICS

ALLO-EVASION™ 1.0 DESIGNED TO OVERCOME 3 MAJOR PATHWAYS OF HOST VS GRAFT



1. Deletion of β2M, a protein required to express HLA-1 on the cell surface prevents recognition by CD8 T cells
2. Knock out of CIITA eliminates HLA-II expression to escape elimination by CD4 T cells
3. Knock-in of HLA-E prevents killing by NK cells

CENTURY THERAPEUTICS

ILLUSTRATIVE POTENTIAL OF ALLO-EVASION™ ON CELLULAR PHARMACOKINETICS



CNTY-101: CAR-iNK CANDIDATE IN R/R B-CELL LYMPHOMA



CNTY-101 may change the lymphoma treatment paradigm given its potential:

- To treat patients immediately upon diagnosis
- To employ milder lymphodepletion regimens
- To enhance overall response rate and duration of response based on the anticipated ability to repeat dose

IND filing on track for mid-2022

- P1 in RR NHL set to initiate 2H22
- Generates POC for CAR iNT therapy and allo-evasion technology

iNK CELL PLATFORM IS OUR MOST ADVANCED PLATFORM

CNTY-101, our first product candidate is a CAR-iNK cell engineered with multiple features



CENTURY THERAPEUTICS

PIPELINE

Product candidate pipeline across cell platforms and targets in solid and hematologic cancers

Product	iPSC Platform	Targets	Indications	Ownership	Expected IND Submission	Discovery	Preclinical	Phase 1	Phase 2	Phase 3
CNTY-101	iNK	CD19	Lymphoma	CENTURY THERAPEUTICS	Mid 2022					
CNTY-103	iNK	CD133 + EGFR	Glioblastoma	CENTURY THERAPEUTICS	1H 2023					
CNTY-102	iT or iNK	CD19 + CD79b	Lymphoma	CENTURY THERAPEUTICS	2H 2023					
CNTY-104	iT or iNK	Multi-specific	Acute Myeloid Leukemia	CENTURY THERAPEUTICS	1H 2024					

Solid Tumors Hematologic Tumors

CENTURY iT CELL PLATFORM: TrueT CELLS WITH TRUSTED TCRs

Currently Exploring Two Major T Cell Subsets To Develop Century's iT Cell Platform





Unique features of Century's iT cell platform:

- Retention of a functional TCR intended to improve iT cell differentiation and functionality
- Use of Trusted αβ **and** γδ which are not expected to mediate GVHD

CENTURY THERAPEUTICS

CAR-iT CELL PLATFORM: γδ CAR-IT CELLS

γδ IT CELLS IS ONE OF THE T CELL PLATFORM OPTIONS WE ARE CURRENTLY EXPLORING TO GENERATE TrueT CELLS

Differentiation of γδ CAR-iT cells from T-iPSC



TrueT Cells



True CAR-iT cells kill lymphoma cells similarly to peripheral blood CAR-T cells



CENTURY THERAPEUTICS

OUR iT CELL PLATFORM IS CLOSELY BEHIND AND MAKING DEMONSTRABLE PROGRESS

Developing αβ and γδ iT platforms with Trusted TCRs that are not expected to cause GvHD



NALM-6 tumor xenograft model

*Statistically significant (p<0.0001)

CENTURY THERAPEUTICS

iPSC-DERIVED γδ iT CELLS MEDIATE SERIAL KILLING AGAINST LYMPHOMA CELLS



CATALYSTS

Event	Estimated Timing
Close IPO with gross proceeds of $243M	2Q21 ✓
Solicit Pre-IND written feedback for CNTY-101	3Q21 ✓
CNTY-101 enters IND enabling studies and manufacturing	**4Q21**
cGMP manufacturing facility in Branchburg NJ expected to be fully operational	**1Q22**
In vivo POC for CNTY-103 in GBM	**1H22**
CNTY-101 IND filing	**Mid-2022**
Initiate CNTY-101 P1 study R/R NHL	**2H22**
Preliminary safety from CNTY-101 P1	**1H23**

CENTURY'S NEXT GENERATION iPSC TECHNOLOGY PLATFORM



iPSC-derived NK cells

iPSC-derived T cells

Precision gene editing

Allo-Evasion™

Protein engineering

Advanced manufacturing

Broad product pipeline with first 1st IND submission targeting Mid-2022